These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27392166)

  • 1. Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents.
    Platton S; Bowles L; MacCallum P
    Br J Haematol; 2017 Nov; 179(3):511-513. PubMed ID: 27392166
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.
    Schultz NH; Holme PA; Bjørnsen S; Henriksson CE; Sandset PM; Jacobsen EM
    Platelets; 2020; 31(1):43-47. PubMed ID: 30569801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
    Clapham RE; Speed V; Czuprynska J; Gazes A; Guppy S; Patel RK; Rea C; Vadher B; Arya R; Roberts LN
    Br J Haematol; 2022 Jan; 196(1):e3-e6. PubMed ID: 34355385
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
    Gessoni G; Valverde S; Gessoni F; Valle R
    Blood Transfus; 2015 Oct; 13(4):666-8. PubMed ID: 25761318
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy.
    Sholzberg M; Xu Y
    JAMA; 2018 Oct; 320(14):1485-1486. PubMed ID: 30242329
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban.
    Pereira Portela C; Stirnimann G; Kröll D; Aliotta A; Veuthey L; Zermatten MG; Alberio L; Bertaggia Calderara D
    Thromb Res; 2024 May; 237():34-36. PubMed ID: 38547692
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebral Venous Thrombosis at High Altitude: Analysis of 28 Cases.
    Hassan WU; Syed MJ; Alamgir W; Awan S; Bell SM; Majid A; Wasay M
    Cerebrovasc Dis; 2019; 48(3-6):184-192. PubMed ID: 31775151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis.
    Fan F; Zou Y; Zhang S; Zhang Y; Lan B; Song Q; Pei M; He L; Wu H; Du Y; Dart AM
    Clin Ther; 2017 Sep; 39(9):1882-1888. PubMed ID: 28823518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
    Lefaucheur R; Le Goff F; Gaillon G; Triquenot-Bagan A; Maltête D
    Presse Med; 2015 Nov; 44(11):1203-4. PubMed ID: 26433836
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban.
    Tardy-Poncet B; Piot M; Montmartin A; Burdier A; Chalayer E; Tardy B
    Thromb Haemost; 2015 Aug; 114(3):652-4. PubMed ID: 26062524
    [No Abstract]   [Full Text] [Related]  

  • 16. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
    Kruger PC; Eikelboom JW; Yusuf S
    Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.
    Chojnowski K; Górski T; Robak M; Treliński J
    Adv Clin Exp Med; 2015; 24(6):995-1000. PubMed ID: 26771971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Camm AJ
    Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombin complex concentrate administration through intraosseous access for reversal of rivaroxaban.
    Means L; Gimbar RP
    Am J Emerg Med; 2016 Mar; 34(3):685.e1-2. PubMed ID: 26403851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.